Treatment and prevention of lipoprotein (a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics
DI Swerdlow, DA Rider, A Yavari… - Cardiovascular …, 2022 - academic.oup.com
Lipid-and lipoprotein-modifying therapies have expanded substantially in the last 25 years,
resulting in reduction in the incidence of major adverse cardiovascular events. However, no …
resulting in reduction in the incidence of major adverse cardiovascular events. However, no …
Lipoprotein (a) in familial hypercholesterolaemia
PN Durrington, B Bashir, D Bhatnagar… - Current opinion in …, 2022 - journals.lww.com
Inheritance of familial hypercholesterolaemia undoubtedly increases the likelihood that
lipoprotein (a) will be raised. However, in familial hypercholesterolaemia when ASCVD …
lipoprotein (a) will be raised. However, in familial hypercholesterolaemia when ASCVD …
[PDF][PDF] Documento de posición de la Sociedad Argentina de Lípidos (SAL) sobre la lipoproteína “a” o Lp (a)
P Corral, JP Nogueira, L Schreier, G Berg, W Masson… - ateroschile.cl
La lipoproteína “a” o Lp (a) es una partícula similar a la lipoproteína de baja densidad (LDL)
unida a la apolipoproteína (Apo [a]). Su valor se determina de forma genética y las medidas …
unida a la apolipoproteína (Apo [a]). Su valor se determina de forma genética y las medidas …